Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach.

Yamamoto Y, Välitalo PA, Wong YC, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Beukers MW, Kokki H, Kokki M, Danhof M, van Hasselt JGC, de Lange ECM.

Eur J Pharm Sci. 2018 Jan 15;112:168-179. doi: 10.1016/j.ejps.2017.11.011. Epub 2017 Nov 11.

PMID:
29133240
2.

Predicting Drug Concentration-Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically-Based Pharmacokinetic Model.

Yamamoto Y, Välitalo PA, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Beukers MW, van den Berg DJ, Hartman R, Wong YC, Danhof M, van Hasselt JGC, de Lange ECM.

CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):765-777. doi: 10.1002/psp4.12250. Epub 2017 Oct 13.

3.

A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects.

Krauwinkel W, Noukens J, van Dijk J, Popa S, Ouatas T, de Vries M, Phung D, Gibbons J, Mordenti J, Mateva L.

J Clin Pharm Ther. 2017 Jun;42(3):268-275. doi: 10.1111/jcpt.12503. Epub 2017 Mar 1.

PMID:
28251667
4.

A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations.

Yamamoto Y, Välitalo PA, van den Berg DJ, Hartman R, van den Brink W, Wong YC, Huntjens DR, Proost JH, Vermeulen A, Krauwinkel W, Bakshi S, Aranzana-Climent V, Marchand S, Dahyot-Fizelier C, Couet W, Danhof M, van Hasselt JG, de Lange EC.

Pharm Res. 2017 Feb;34(2):333-351. doi: 10.1007/s11095-016-2065-3. Epub 2016 Nov 18.

5.

The variability in beta-cell function in placebo-treated subjects with type 2 diabetes: application of the weight-HbA1c-insulin-glucose (WHIG) model.

Duong JK, de Winter W, Choy S, Plock N, Naik H, Krauwinkel W, Visser SA, Verhamme KM, Sturkenboom MC, Stricker BH, Danhof M.

Br J Clin Pharmacol. 2017 Mar;83(3):487-497. doi: 10.1111/bcp.13144. Epub 2016 Nov 17.

6.

Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.

Groen-Wijnberg M, van Dijk J, Krauwinkel W, Kerbusch V, Meijer J, Tretter R, Zhang W, van Gelderen M.

Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):417-429. doi: 10.1007/s13318-016-0350-5.

PMID:
27350625
7.

Pharmacokinetic Drug Interaction Studies with Enzalutamide.

Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, Mol R, Mordenti J, Ouatas T.

Clin Pharmacokinet. 2015 Oct;54(10):1057-69. doi: 10.1007/s40262-015-0283-1.

8.

Clinical Pharmacokinetic Studies of Enzalutamide.

Gibbons JA, Ouatas T, Krauwinkel W, Ohtsu Y, van der Walt JS, Beddo V, de Vries M, Mordenti J.

Clin Pharmacokinet. 2015 Oct;54(10):1043-55. doi: 10.1007/s40262-015-0271-5.

9.

Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.

Kadokura T, Zhang W, Krauwinkel W, Leeflang S, Keirns J, Taniuchi Y, Nakajo I, Smulders R.

Clin Pharmacokinet. 2014 Nov;53(11):975-88. doi: 10.1007/s40262-014-0180-z. Review.

PMID:
25316572
10.

Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men.

van Gelderen M, Tretter R, Meijer J, Dorrepaal C, Gangaram-Panday S, Brooks A, Krauwinkel W, Dickinson J.

Int J Clin Pharmacol Ther. 2014 Aug;52(8):693-701. doi: 10.5414/CP201979.

PMID:
24755125
11.

Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.

Zhang W, Smulders R, Abeyratne A, Dietz A, Krauwinkel W, Kadokura T, Keirns J.

Clin Ther. 2013 Aug;35(8):1150-1161.e3. doi: 10.1016/j.clinthera.2013.06.009. Epub 2013 Aug 2.

PMID:
23910665
12.

Evaluation of the Pharmacokinetic Interaction Between the β3 -Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects.

Krauwinkel WJ, Kerbusch VM, Meijer J, Tretter R, Strabach G, Van Gelderen EM.

Clin Pharmacol Drug Dev. 2013 Jul;2(3):255-63. doi: 10.1002/cpdd.37. Epub 2013 May 14.

PMID:
27121787
13.

The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.

Zhang W, Krauwinkel WJ, Keirns J, Townsend RW, Lasseter KC, Plumb L, Kadokura T, Ushigome F, Smulders R.

Clin Drug Investig. 2013 Jul;33(7):489-96. doi: 10.1007/s40261-013-0089-6.

PMID:
23733389
14.

The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.

Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, Strabach G, van Gelderen M.

Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):43-52. doi: 10.1007/s13318-013-0133-1. Epub 2013 Jun 1.

PMID:
23728524
15.

Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.

Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J.

Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y.

PMID:
23625188
16.

Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.

Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupčová V, van Gelderen M.

Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3.

PMID:
23208320
17.

Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.

Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M.

Clin Ther. 2012 Oct;34(10):2144-60. doi: 10.1016/j.clinthera.2012.09.010.

PMID:
23063375
18.

No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.

Smulders RA, Zhang W, Veltkamp SA, van Dijk J, Krauwinkel WJ, Keirns J, Kadokura T.

Diabetes Obes Metab. 2012 Oct;14(10):937-43. doi: 10.1111/j.1463-1326.2012.01624.x. Epub 2012 Jun 7.

PMID:
22587345
19.

Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.

Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T.

Drug Metab Dispos. 2012 Apr;40(4):815-24. doi: 10.1124/dmd.111.043588. Epub 2012 Jan 23.

20.

Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.

Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA.

Clin Drug Investig. 2011 Dec 1;31(12):839-51. doi: 10.2165/11594330-000000000-00000.

PMID:
21877761
21.

Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity?

Korstanje C, Krauwinkel W, van Doesum-Wolters FL.

Br J Clin Pharmacol. 2011 Aug;72(2):218-25. doi: 10.1111/j.1365-2125.2010.03870.x.

22.

A semiphysiological population model for prediction of the pharmacokinetics of drugs under liver and renal disease conditions.

Strougo A, Yassen A, Krauwinkel W, Danhof M, Freijer J.

Drug Metab Dispos. 2011 Jul;39(7):1278-87. doi: 10.1124/dmd.110.037838. Epub 2011 Apr 12. Erratum in: Drug Metab Dispos. 2012 Jul;40(7):1449.

23.

Specific pharmacokinetic aspects of the urinary tract.

Korstanje C, Krauwinkel W.

Handb Exp Pharmacol. 2011;(202):267-82. doi: 10.1007/978-3-642-16499-6_13. Review.

PMID:
21290231
24.

An example of optimal phase II design for exposure response modelling.

Maloney A, Schaddelee M, Freijer J, Krauwinkel W, van Gelderen M, Jacqmin P, Simonsson US.

J Pharmacokinet Pharmacodyn. 2010 Oct;37(5):475-91. doi: 10.1007/s10928-010-9168-y. Epub 2010 Sep 25.

PMID:
20872056
25.

The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects.

Kadokura T, den Adel M, Krauwinkel WJ, Takeshige T, Nishida A.

Eur J Clin Pharmacol. 2008 Jul;64(7):691-5. doi: 10.1007/s00228-008-0466-x. Epub 2008 Apr 26.

PMID:
18438654
26.

The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects.

Kadokura T, den Adel M, Krauwinkel WJ, Takeshige T, Nishida A.

Eur J Clin Pharmacol. 2008 Jun;64(6):605-9. doi: 10.1007/s00228-008-0472-z.

PMID:
18401578
27.

Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency.

Smulders RA, Smith NN, Krauwinkel WJ, Hoon TJ.

J Pharmacol Sci. 2007 Jan;103(1):67-74.

28.

Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment.

Kuipers M, Smulders R, Krauwinkel W, Hoon T.

J Pharmacol Sci. 2006 Dec;102(4):405-12.

29.

Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.

Swart PJ, Krauwinkel WJ, Smulders RA, Smith NN.

Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):33-6.

31.

Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.

Taekema-Roelvink ME, Swart PJ, Kuipers ME, Krauwinkel WJ, Visser N, Smulders RA.

Clin Ther. 2005 Sep;27(9):1403-10.

PMID:
16291413
32.

Effect of age on the pharmacokinetics of solifenacin in men and women.

Krauwinkel WJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink ME.

Int J Clin Pharmacol Ther. 2005 May;43(5):227-38.

PMID:
15906588
33.

Pharmacokinetics and safety of solifenacin succinate in healthy young men.

Smulders RA, Krauwinkel WJ, Swart PJ, Huang M.

J Clin Pharmacol. 2004 Sep;44(9):1023-33.

PMID:
15317830
34.

Solifenacin demonstrates high absolute bioavailability in healthy men.

Kuipers ME, Krauwinkel WJ, Mulder H, Visser N.

Drugs R D. 2004;5(2):73-81.

PMID:
15293866
35.
36.

Bismuth biokinetics and kidney histopathology after bismuth overdose in rats.

Leussink BT, Slikkerveer A, Krauwinkel WJ, van der Voet GB, de Heer E, de Wolff FA, Bruijn JA.

Arch Toxicol. 2000 Sep;74(7):349-55.

PMID:
11043489
37.

The gastrointestinal passage and release of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers.

Burggraaf J, van Haarst AD, Fockens P, Schoemaker HC, Krauwinkel WJ, Cohen AF.

Br J Clin Pharmacol. 1998 Sep;46(3):207-14.

38.

Pharmacokinetics of tamsulosin in subjects with normal and varying degrees of impaired renal function: an open-label single-dose and multiple-dose study.

Wolzt M, Fabrizii V, Dorner GT, Zanaschka G, Leufkens P, Krauwinkel WJ, Eichler HG.

Eur J Clin Pharmacol. 1998 Jun;54(4):367-73.

PMID:
9696967
39.

Multiple dose bioequivalence study with josamycin propionate, a drug with highly variable kinetics, in healthy volunteers.

Van Hoogdalem EJ, Terpstra IJ, Krauwinkel WJ, Volkers-Kamermans NJ, Baven AL, Verschoor JS.

Int J Clin Pharmacol Ther. 1996 May;34(5):202-7.

PMID:
8738856
40.

Determination of penicillin-V in human plasma by high-performance liquid chromatography and solid-phase extraction.

Krauwinkel WJ, Volkers-Kamermans NJ.

J Chromatogr B Biomed Appl. 1996 Apr 26;679(1-2):129-35.

PMID:
8998551
41.

Determination of amoxicillin in human plasma by high-performance liquid chromatography and solid phase extraction.

Krauwinkel WJ, Volkers-Kamermans NJ, van Zijtveld J.

J Chromatogr. 1993 Aug 11;617(2):334-8.

PMID:
8408402

Supplemental Content

Loading ...
Support Center